Investing.com — Actinium制药公司（NYSE AMERICAN: ATNM），一家专注于靶向放射治疗的公司，已从Eckert & Ziegler获得了放射性同位素锕-225（Ac-225）的供应，旨在推进其国内外癌症治疗的临床试验。

Title: ATNM-400 is a novel Actinium-225 antibody radioconjugate with strong efficacy in preclinical models of prostate cancer ...

Actinium正在推进ATNM-400的研发，预计将从Pluvicto耐药性前列腺癌模型中获得更多数据。该公司更广泛的研发重点包括几个针对实体瘤适应症的临床前项目，利用其拥有的230项与靶向放射疗法和Ac-225制造相关的专利和专利申请组合。

Actinium announced ATNM-400, a novel, non-PSMA targeting, first in class radiotherapy for prostate cancer utilizing the Actinium-225 ...

Actinium Pharma inks supply agreement with Eckert & Ziegler for Ac-225 radioisotope to support comprehensive development activities: New York Wednesday, March 26, 2025, 18:00 Hrs ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply ...

Agreement/Incoming OrdersEckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities 25.03.2025 / 09:30 CET/CESTThe issuer is solely responsible for the ...

today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler ...

Finally, we look forward to fully leveraging our proprietary Actinium-225 cyclotron manufacturing technology to meet our projected demand given our expanding Actinium-225 programs as well as ...

Actinium-225 offers a different approach by using alpha particles instead of beta particles. Alpha particles are highly energetic and travel only a short distance, which allows them to effectively ...